Showing 2881-2890 of 10619 results for "".
Real-World Effectiveness of Liraglutide for Obesity: Multicenter Data From Turkey
https://reachmd.com/programs/clinicians-roundtable/real-world-effectiveness-of-liraglutide-for-obesity-multicenter-data-from-turkey/39655/A large retrospective study across 38 endocrinology clinics in Turkey showed that liraglutide led to meaningful weight loss and metabolic improvements—even at slightly reduced doses. Hear from ReachMD's Ryan Quigley as he reviews recent real-world data on this GLP-1 receptor agonist.Cadherin-6 in Focus: Existing Antibodies, Emerging Applications
https://reachmd.com/programs/living-rheum/cadherin-6-in-focus-existing-antibodies-emerging-applications/32796/While cadherin-6 may not yet shift clinical practice in rheumatoid arthritis, its role as a surface-expressed, actionable target opens the door to rapid therapeutic development—particularly with existing antibodies already in clinical trials for urologic cancers. Dr. Gary Firestein discussesAdvancing MS Care: Diagnostic Clarity, Early Action, and Patient-Centered Treatment
https://reachmd.com/programs/frontlines-multiple-sclerosis/advancing-ms-care-diagnostic-clarity-early-action-and-patient-centered-treatment/36391/With the latest revisions to the McDonald criteria and new therapies on the horizon, multiple sclerosis (MS) care is entering a pivotal phase. In this expert-led discussion, Dr. Gates Colbert sits down with Dr. Tirisham Gyang to unpack how emerging diagnostic tools, earlier intervention strategies,Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
https://reachmd.com/programs/neurofrontiers/understanding-antibody-mediated-demyelinating-diseases-key-differences-from-ms/32821/Antibody-mediated demyelinating diseases, such as neuromyelitis optica spectrum disorder and MOG antibody disease, differ fundamentally from multiple sclerosis (MS) due to their association with specific antibodies. Dr. Michael Levy explains how these conditions progress, how relapses can driRefining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
https://reachmd.com/programs/project-oncology/refining-multimodal-therapy-for-mesothelioma-clinical-impact-of-smart-sequencing/36559/Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he discusses the rationale behind this decade-long clinical advancement, which he spoke about at tNavigating Iron Deficiency Anemia: A Practical Guide for Gastroenterologists
https://reachmd.com/programs/gi-insights/program-name/36501/Iron deficiency anemia is common in gastroenterology patients and is often underrecognized or suboptimally managed. That's why targeted treatment is essential to improve patient outcomes. In this expert-led discussion, Dr. Peter Buch and Dr. Thomas DeLoughery outline what gastroenterologists need tThe Skin and the Pursuit of Beauty
https://reachmd.com/topics/skincare/the-skin-and-the-pursuit-of-beauty/36685/With Steven H. Dayan, MD, FACSCardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks
https://reachmd.com/programs/project-oncology/cardiac-complications-in-sickle-cell-disease-emerging-evidence-and-risks/35929/Cardiopulmonary complications are a leading cause of early mortality in adults with sickle cell disease, with evidence showing that cardiac injury may begin as early as childhood. However, despite the severity of these issues, there are currently no uniform guidelines for asymptomatic cardiac screenAssessing Sex-Based Treatment Responses to Gepants In Migraine Management
https://reachmd.com/programs/frontlines-migraine/assessing-sex-based-treatment-responses-to-gepants-in-migraine-management/36157/A secondary analysis of eight clinical trials assessed the efficacy of ubrogepant and atogepant in both acute and preventive migraine treatments. Dive into these findings and explore implications for the future of migraine care.Optimizing Schizophrenia Care: Strategies for Managing Side Effects and Treatment Resistance
https://reachmd.com/programs/frontlines-schizophrenia/optimizing-schizophrenia-care-strategies-for-managing-side-effects-and-treatment-resistance/30035/Learn about strategies for managing common therapeutic challenges in schizophrenia.